B、C基因型与拉米夫定抗HBV疗效的比较

The virology response of lamivudine with HBV genotype B compare with genotype C

目的了解乙肝病毒(HBV)B、C基因型与拉米夫定抗HBV的关系。方法采用前瞻性和回顾性相结合的方法收集资料,患者口服拉米夫定100 mg/d治疗至少12个月,停药观察至少6个月。采用多引物对巢式PCR法检测HBV基因型。结果共收集并检测出C基因型24例,B基因型22例。B、C基因型患者的病毒学应答在服药6个月、服药12个月及停药时无统计学意义,停药6个月后的病毒学应答有统计学意义,B基因型优于C基因型。结论B基因型患者停药6个月后的持续病毒学应答优于C基因型。

Objective To evaluate the antiviral response of lamivudine treatment between HBV genotypes B and C in chronic patients with HBV infection. Methods Clinical data was collected by prospective method linked retrospective method. The patients with HBV infection received lamivudine 100 mg/d,oral application for at least 12 months and observed regularly until 6 months after drug withdrawal. HBV genotype was determined by the nested PCR with multiple x pairs of primers. Results There were 22 patients of genotype B and 24 of genotype C. The virology respond was not significant difference between genotype B and Genotype C at time of 6 months, 12 months and the time of drug withdrawal. It was significant difference at 6 months after drug withdrawal. Conclusion The sustained virology respond with genotype B was higher than with genotype C after 6 month of lamivudine withdrawal.